drugset / Trial / NCT00216671

Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

NCT00216671

Phase 4 Completed 220 enrolled Janssen Pharmaceutica N.V., Belgium
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this randomized trial was to investigate whether early initiation of treatment with Risperdal Consta after an acute episode was not inferior to the routine approach (oral treatment for 12 weeks followed by treatment with Risperdal Consta). .

Timeline

Start
2005-11
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 25 mg Intramuscular
Subject Risperidone Other / unclassified 50 mg Intramuscular

Indications